TY - JOUR
T1 - Targeted systemic therapies for hepatocellular carcinoma
T2 - Clinical perspectives, challenges and implications
AU - Frenette, Catherine
AU - Gish, Robert
PY - 2012/2/14
Y1 - 2012/2/14
KW - Angiogenesis
KW - Brivanib
KW - Fibroblast growth factor
KW - Hepatocellular carcinoma
KW - Sorafenib
KW - Tumor response
KW - Vascular endothelial growth factor
KW - Humans
KW - Antineoplastic Agents/therapeutic use
KW - Neovascularization, Pathologic
KW - Treatment Outcome
KW - Clinical Trials as Topic
KW - Carcinoma, Hepatocellular/drug therapy
KW - Angiogenesis Inhibitors/therapeutic use
KW - Liver Neoplasms/drug therapy
UR - https://www.scopus.com/pages/publications/84857020475
UR - https://www.scopus.com/pages/publications/84857020475#tab=citedBy
UR - https://www.mendeley.com/catalogue/72438d4d-4591-325a-8c52-3f67d8a0130c/
U2 - 10.3748/wjg.v18.i6.498
DO - 10.3748/wjg.v18.i6.498
M3 - Review article
C2 - 22363115
AN - SCOPUS:84857020475
SN - 1007-9327
VL - 18
SP - 498
EP - 506
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
IS - 6
ER -